Does Blue Cross Blue Shield Cover Lantus?

How BCBS Formulary Coverage Works for Lantus

Blue Cross Blue Shield is not a single insurer. It operates as a federation of 34 independent, locally operated companies serving all 50 states 1. Each affiliate maintains its own formulary, negotiates its own rebate contracts with pharmaceutical manufacturers, and sets its own tier structure. This means coverage for Lantus (insulin glargine U-100, manufactured by Sanofi) can differ significantly between BCBS of Texas and BCBS of Massachusetts.

Most BCBS commercial plans place Lantus on Tier 2 or Tier 3 of their drug formularies. Tier 2 placement typically carries a copay between $25 and $50 for a 30-day supply. Tier 3 means the plan considers it non-preferred, pushing copays to $50 to $100 or higher. The distinction often depends on whether the plan has a rebate agreement with Sanofi or has shifted preference to a biosimilar insulin glargine product 2.

A 2022 analysis published in Diabetes Care found that formulary restrictions on insulin products increased by 37% between 2016 and 2021 across major commercial insurers, including BCBS affiliates 3. Patients should always verify their specific plan's formulary through the BCBS member portal or by calling the number on their insurance card.

The Role of Biosimilars in BCBS Lantus Coverage

The FDA has approved several biosimilar and follow-on insulin glargine products that are therapeutically equivalent to Lantus. These include Basaglar (Eli Lilly), Semglee (Mylan/Viatris), and Rezvoglar (Eli Lilly) 4. Many BCBS affiliates now designate one or more of these products as the preferred long-acting basal insulin on their formularies, moving brand-name Lantus to a higher, more expensive tier.

This shift has real financial consequences. A patient on a BCBS plan that prefers Semglee might pay a $25 copay for Semglee but $75 for Lantus. In some cases, BCBS plans will not cover Lantus at all without a prior authorization demonstrating medical necessity for the brand-name product over its biosimilar equivalents.

The clinical evidence supports this approach. A 2023 systematic review in the Annals of Internal Medicine evaluated 11 randomized controlled trials comparing biosimilar insulin glargine to Lantus and found no clinically meaningful differences in HbA1c reduction, hypoglycemia rates, or immunogenicity 5. Mean HbA1c reductions were within 0.1% of each other across all comparisons, and the 95% confidence intervals consistently crossed zero.

For patients who have been stable on Lantus, switching to a biosimilar is generally safe. The American Diabetes Association (ADA) 2024 Standards of Care notes that biosimilar insulins "can be expected to produce the same clinical result as their reference product in any given patient" 6.

Prior Authorization and Step Therapy Requirements

Some BCBS affiliates require prior authorization (PA) before approving coverage for brand-name Lantus. PA is more common when the plan's formulary prefers a biosimilar alternative. The typical PA process involves the prescribing physician submitting documentation showing why the patient needs Lantus specifically rather than a preferred biosimilar.

Common reasons that satisfy PA criteria include:

• Documented adverse reaction or intolerance to the preferred biosimilar product
• Clinical instability after switching from Lantus to a biosimilar (verified by HbA1c or continuous glucose monitoring data)
• Allergy to an inactive ingredient unique to the biosimilar formulation

Step therapy is a related but distinct requirement. Under step therapy protocols, BCBS may require the patient to try and fail a preferred insulin glargine product before the plan will cover Lantus. A 2021 study in JAMA Internal Medicine found that step therapy for insulin products was associated with a 14-day average delay in medication access, with 8.3% of patients experiencing a gap in therapy during the transition period 7.

Patients and providers can appeal step therapy requirements. Most BCBS plans have a formal exceptions process, and the ADA has published guidance for clinicians on navigating insurance barriers to insulin access [6].

BCBS Medicare Advantage and Part D Coverage for Lantus

The Inflation Reduction Act (IRA), signed into law in August 2022, capped out-of-pocket insulin costs at $35 per month for Medicare Part D beneficiaries starting January 1, 2023 8. This cap applies to all covered insulin products, including Lantus, regardless of formulary tier.

BCBS Medicare Advantage plans with Part D drug benefits must comply with this cap. A beneficiary enrolled in a BCBS Medicare Advantage plan who uses Lantus will pay no more than $35 per 30-day supply at the pharmacy, even if Lantus is placed on a non-preferred tier. The cap applies at the point of sale, meaning patients see the reduced cost immediately rather than waiting for reimbursement.

For 2025 and 2026, the IRA also introduced an annual out-of-pocket spending cap of $2,000 for all Part D prescription drugs 9. This benefits patients using multiple medications alongside Lantus, as total annual drug costs are now limited regardless of the number of prescriptions.

One detail that catches patients off guard: the $35 cap applies per insulin product, not per insulin unit. A patient using both Lantus (basal) and a rapid-acting insulin like Humalog would pay up to $35 for each product per month, totaling $70.

BCBS Marketplace (ACA) Plan Coverage

Individuals purchasing coverage through the Affordable Care Act (ACA) marketplace may find BCBS plans with varying Lantus coverage. ACA plans must cover at least one drug in every pharmacological class, and long-acting insulin is a required class. This guarantees that every BCBS marketplace plan covers at least one insulin glargine product, though it may be a biosimilar rather than brand-name Lantus 10.

Some states have enacted additional insulin affordability laws that apply to marketplace plans. As of 2025, more than 25 states have passed legislation capping insulin copays for state-regulated health plans, with caps typically ranging from $25 to $50 per 30-day supply 11. These state laws apply to BCBS plans regulated in those states.

Patients on high-deductible health plans (HDHPs) with BCBS should note that insulin is classified as a preventive drug under IRS Notice 2019-45, meaning HDHPs can cover insulin before the deductible is met 12. Not all BCBS HDHPs have adopted this provision, so patients should verify with their plan.

Out-of-Pocket Cost Reduction Strategies

Even with insurance, Lantus can be expensive. The wholesale acquisition cost (WAC) for Lantus SoloSTAR (5 pens, 3 mL each) is approximately $420, though insured patients rarely pay the full amount 13. Several strategies can reduce costs for BCBS members.

Sanofi Insulins ValYou Savings Program. Eligible patients without insurance or with commercial insurance can access Lantus for a maximum of $99 per month for up to 10 boxes of pens or 10 vials. This program does not apply to patients on government insurance (Medicare, Medicaid, TRICARE).

Request the preferred biosimilar. If the BCBS plan prefers Semglee or Basaglar, switching to the preferred product is the most straightforward way to lower copays. Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has stated: "For the vast majority of patients, biosimilar insulin glargine is clinically interchangeable with Lantus. The data are clear on this point" [5].

Use the BCBS mail-order pharmacy. Many BCBS plans offer a 90-day supply through their mail-order pharmacy at a lower per-unit cost than retail. A 90-day supply might cost 2 to 2.5 times the 30-day copay rather than 3 times.

Apply for Sanofi Patient Assistance. Patients with household income below 400% of the federal poverty level may qualify for free Lantus through Sanofi's patient assistance program.

Check state insulin safety net programs. Several states, including Minnesota, Colorado, and Illinois, have emergency insulin access programs that provide a 30-day supply for $35 or less, regardless of insurance status [11].

How to Verify Your Specific BCBS Coverage

Because BCBS operates through independent affiliates, the most reliable way to confirm Lantus coverage is to check your specific plan. Three steps.

First, log into your BCBS member portal and search the formulary for "insulin glargine" or "Lantus." The formulary will show the tier, any prior authorization requirements, and any quantity limits. Second, call the member services number on your insurance card and ask specifically whether Lantus requires PA or step therapy, and what the expected copay is at your preferred pharmacy. Third, ask your pharmacist to run a test claim. A test claim shows the exact copay amount your plan will charge before you commit to filling the prescription.

If Lantus is not covered or is placed on a high-cost tier, ask your physician to submit a formulary exception request. The ADA recommends that physicians document the clinical rationale, including any history of adverse reactions to alternative products, HbA1c trends, and glucose variability data from continuous glucose monitoring [6].

Clinical Context: Why Lantus Remains Widely Prescribed

Lantus was the first long-acting insulin analog approved by the FDA, receiving approval in April 2000 14. It provides approximately 24 hours of basal insulin coverage with a relatively peakless action profile, reducing the risk of nocturnal hypoglycemia compared to older NPH insulin.

The ORIGIN trial (N=12,537) demonstrated that insulin glargine used early in the course of type 2 diabetes was associated with a neutral cardiovascular outcome profile over a median follow-up of 6.2 years 15. The trial also found no increased risk of cancer, addressing a concern raised by earlier observational studies. The study concluded that "insulin glargine had a neutral effect on cardiovascular outcomes and cancers" compared to standard care.

More than two decades of post-marketing data support Lantus's safety profile. The FDA's Adverse Event Reporting System shows a stable safety signal with no new major concerns emerging since approval [14]. This long track record is one reason some clinicians and patients prefer brand-name Lantus over newer biosimilar alternatives, even when the clinical data show equivalence.

A 2024 real-world analysis of over 40,000 patients published in Diabetes Care found that non-medical switching from Lantus to biosimilar insulin glargine was not associated with worsened glycemic control (mean HbA1c change: +0.04%, 95% CI: -0.02 to +0.10) or increased hypoglycemia events over 12 months of follow-up 16.